Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma

Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Megan M. Saraceni, Emma Scott, Richard T. Maziarz, Matthew B. Siegel, Solange Bassale, Susie Jiing, Eva Medvedova Tags: Original Study Source Type: research